Summary

ㅁ Title: The 3rd Meeting on Access to Medicines under Universal Health Coverage in the Asia Pacific Region  ㅁ Date: 22 - 23 September 2016  ㅁ Venue: Novotel Ambassador Gangnam, Seoul, Korea  ㅁ Hosted by OECD KOREA Policy Centre (Health and Social Policy Programme), OECD, WHO WPRO,       WHO Collaborating Centre (at SNU)  ㅁ Participation: 40 persons     ㅇ Medicines experts from the Asia Pacific countries     ㅇ International organizations: OECD, WHO, WHO WPRO, WHO SEARO, UNDP, ADB

Programme Summary

        ㅁ 22 September 2016 

          1.1 Opening and welcome address
    ㆍ Ra, Sung-woong, Director General , OECD KOREA Policy Centre 
    ㆍ David Newby, Coordinator, WHO WPRO 
    ㆍ Sun-Young Kim, Professor, WHO Collaborating Centre (at SNU) 
    ㆍ Luca Lorenzoni, Health Economist, OECD

           Overview of meeting objectives 
    Nomination of Chair and co-chair 
    Participant introduction
    Group photo

          1.2 Initiatives promoting wider access to medicines
    ㆍ Global update on access to medicines – Inthira Yamabhai, WHO HQ
    ㆍ Regional update on access to medicines in Asia Pacific – Klara Tisocki, WHO SEARO
    ㆍ Pharmaceutical Country Profiles and PIEMEDS – Uhjin Kim, WHO WPRO 
    ㆍ The effect of generic medicines policies on price reductions: Lessons from Australia, Korea, Singapore,

                and New Zealand – Libby Roughead, Temporary Adviser

          1.3 Financing options for medicines
    ㆍ Health at a glance Asia Pacific 2016 – Luca Lorenzoni, OECD
    ㆍ Pharmacoeconomics and resource allocation for high cost medicines – David Newby, WHO WPRO
    ㆍ Financing and benefit package decisions – Soonman Kwon, ADB

          1.4 Group Work
    ㆍ Root cause analysis and identification of challenges in access to high cost medicines 
    ㆍ Group work feedback and discussions

 ㅁ 23 September 2016 

          2.1 Factors that influence health technology adoption 
    ㆍ Considerations in expanding access to high-cost medicines in low-  and middle-income countries:

                Financial, economic, organizational, and ethical issues – Sun-Young Kim, WHO Collaborating Centre
    ㆍ Looking back on HTA during Universal Coverage Scheme implementation: Lessons from Thailand

                – Netnapis Suchonwanich, HITAP, Thailand

           ㆍ Challenges in introducing a high cost medicines in Vietnam – Vu Thi Chi, DAV, Vietnam

           ㆍ Panel Discussion: Factors that influence health technology adoption

                – Facilitator: Soonman Kwon

                – Panelists: Inthira Yamabhai, Sun-Young Kim, Andrew Wilson, Luca Lorenzoni, Libby Rougheadd

          2.2 Country cases
           ㆍ Access to oncology medication in Australia – Andrew Wilson, Temporary Adviser 
           ㆍ Access to HepC medicine: experience from Korea – Junho Jang, HIRA, Korea

           ㆍ Lao PDR’s experience in introducing a high cost medicines – Sivong Sengaloundeth, FDD, Lao PDR

           ㆍ High cost medicines: what do we do – Abida Syed M. Haq, MoH, Malaysia

          2.3 Group work

           ㆍ Identification of factors and players that influence health technology adoption in countries

           ㆍ Group work feedback and discussions 

          2.4 Conclusions and Closure

           ㆍ Meeting summary – Plenary Chair  

           ㆍ Comments by the meeting organizers

           ㆍ Closing remarks – Ra, Sung-woong, Director General, OECD KOREA Policy Centre